Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Artios Banks On DNA Repair To Challenge IO Space

Executive Summary

With a better understanding of how DNA damage repair (DDR) pathways operate in cancer cells, UK biotech Artios Pharma, in partnership with Cancer Research UK, is looking to develop drug candidates that can selectively kill tumor cells. Speaking at the Biotech Showcase 2018, Artios CEO Niall Martin told Scrip how the company is advancing its lead programs towards the clinic and is seeking series B venture capital to demonstrate proof of concept for the lead programs.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC100519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel